Quantum Computing Inc. - Common Stock (QUBT)

Traders "flipped" Quantum Computing stock for a quick profit last time. Will it happen again?

As of October 2025, a palpable buzz permeates the financial markets, centered on a technology still largely shrouded in scientific complexity: quantum computing. Wall Street, ever in pursuit of the next transformative investment, has increasingly turned its gaze towards quantum computing stocks, embracing them as a new, albeit intricate, favorite

The company announced a private placement offering, which is expected to generate approximately $750 million in gross proceeds, with the deal anticipated to be finalized around Oct. 8, 2025.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

The share price is up big, but Quantum Computing is still a highly speculative investment.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Quantum Computing stock is seeing another day of powerful bullish momentum.

Are the same people who bought Quantum Computing stock last week selling it this week?

Quantum stocks–Rigetti, D-Wave and Quantum Computing–were popping on Friday after trending across social media for most of the week.

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Rigetti jumped 84% in September, outpacing every other quantum stock. Spoiler alert: The contracts behind the surge may not justify the billions added to its market cap.

Hope and hype could last longer than you think with this popular quantum computing play.

Some parts of the market are looking pretty frothy.

Some quantum stocks pulled back from all-time highs this week as investors rotated out of speculative names and into more defensive positions. 

The company announced a private placement earlier this week.

Quantum Computing stock has the money it needs to keep burning cash for years -- and it will.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.

To gain an edge, this is what you need to know today.

As the artificial intelligence revolution continues to reshape industries and captivate investors, the spotlight has largely remained fixed on a handful of tech behemoths, often dubbed the "Magnificent Seven." These established players have driven much of the initial AI excitement and market gains. However, a growing chorus of analysts and